SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical trials for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS explained in plain language.
Never miss a new study
Get alerted when new SLE - SYSTEMIC LUPUS ERYTHEMATOSUS trials appear
Sign up with your email to follow new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on lupus and scleroderma in new trial
Disease control Recruiting nowThis early-stage study tests a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that cause autoimmune diseases like lupus and scleroderma. The treatment is given as a one-time infusion and aims to control d…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New lupus drug candidate enters human testing
Disease control Recruiting nowThis early-stage study tests a new drug called CC312 in 32 adults with moderate-to-severe lupus. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either CC312 or a placebo, and researchers will monitor side effects and measure d…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Lupus patients may get new hope from engineered immune cells
Disease control Recruiting nowThis study tests a new treatment called MB-CART19.1 for people with severe systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. The…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: PHASE1, PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC
-
New drug aims to calm overactive immune system in lupus and related diseases
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug, CC312, in 6 adults with lupus, inflammatory myopathies, or systemic sclerosis that have not responded to standard treatments. The study will look for side effects and measure how the drug behaves in the body. It is not expect…
Matched conditions: SLE - SYSTEMIC LUPUS ERYTHEMATOSUS
Phase: EARLY_PHASE1 • Sponsor: CytoCares Inc • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC